ADC Spikes After Enrollment Update on Confirmatory Trial for Lymphoma Therapy

Seeking Alpha20:15

ADC Completes Enrollment in Late-Stage Zynlonta Combination Trial

MT Newswires07:02

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

BusinesswireDec 16 18:00

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs With Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS

PR NewswireDec 13 08:00

ADC Therapeutics Price Target Maintained With a $10.00/Share by Guggenheim

Dow JonesDec 12 23:40 · Ratings

ADC Therapeutics Analyst Ratings

BenzingaDec 12 01:59 · Ratings